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ABSTRACT 
In subjects with aortic regurgitation (AR) or mitral regurgitation (MR), transthoracic echocardiography 
(TTE) is recommended for surveillance. Few prospective studies have directly compared the ability of 
TTE and cardiac magnetic resonance (CMR) to predict clinical outcomes in AR and MR. We hypothesized 
that, given its higher reproducibility, CMR would predict the need for valve surgery or heart failure (HF) 
hospitalization better than TTE. Quantitative TTE and CMR were performed on the same day for 51 
subjects: 29 with chronic AR and 22 with chronic, primary MR for quantification of valve regurgitation. 
Baseline measures of valve regurgitation were compared to the combined primary endpoint of new HF 
and valve surgery using receiver operating characteristics, simple logistic regression and Kaplan-Meier 
survival analyses. The primary endpoint occurred in 5 AR subjects (all surgery) and 8 MR subjects (7 
surgery, 1 HF) after a mean follow-up of 4.4 ± 1.5 years. For AR, CMR-derived regurgitant volume >50mL 
identified those at high risk with 50% undergoing valve surgery versus 0% for those with regurgitant 
volume ≤50 ml, and was more strongly associated with outcomes than regurgitant volume by TTE 
(p<0.05). For MR, 6.8% of those with regurgitant volume by TTE ≤30 mL developed the primary endpoint 
versus 70% in those with regurgitant volume >30 mL. Regurgitant volume by CMR showed no significant 
separation of survival curves for MR. In conclusion, regurgitant volume by CMR was more predictive of 
outcomes than by TTE in subjects with AR. In MR, the two modalities performed similarly.  
 
Keywords: Aortic regurgitation, Mitral Regurgitation, Echocardiography, Cardiac Magnetic Resonance 
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Subjects with chronic aortic regurgitation (AR) or mitral regurgitation (MR) require valve repair or 
replacement prior to the development of left ventricular (LV) systolic dysfunction or irreversible 
ventricular dilation. Transthoracic echocardiography (TTE) is widely used to determine the optimal 
timing for valve surgery in asymptomatic subjects with chronic AR or MR.
1–10
 However, TTE has potential 
limitations including poor acoustic windows, eccentric jets and geometric assumptions. Cardiac 
magnetic resonance imaging (CMR) can also be used to evaluate AR and MR severity, LV volumes and 
function. However, there is relatively little literature to correlate CMR measures of valve dysfunction 
with clinical outcomes.
11–17
 We have previously shown that CMR is more reproducible than TTE in 
quantification of AR and MR severity with less inter-observer and intra-observer variability.
18
 The 
purpose of the current study was to determine how measurements made by TTE and CMR correlate 
with clinical outcomes in subjects with AR or MR. We hypothesized that measurements obtained by 
CMR may be superior to TTE for predicting the development of the primary composite endpoint of 
undergoing valve surgery for the primary indication of valve regurgitation or hospitalization for valvular 
HF in subjects with chronic AR and chronic, primary MR who did not have indications for valve surgery at 
baseline.  
Methods 
 Subject enrollment and imaging procedures were previously described.
18
 Briefly, 31 
asymptomatic adults with chronic AR and 26 asymptomatic adults with chronic MR were prospectively 
enrolled and underwent CMR and 2-dimensional TTE with Doppler on the same day from January 2008 
to July 2010. TTE measurements were made by two experienced observers (C.M.O. and P.J.C.) blinded to 
all other TTE and CMR measurements. Similarly blinded CMR measurements were made by 2 
experienced physicians (P.J.C. and C.H.C.). Subjects had mild to severe valve regurgitation. Exclusion 
criteria were more than mild regurgitation of a second valve, more than mild valve stenosis, atrial 
fibrillation at the time of imaging, known poor acoustic windows, extreme claustrophobia and non-MRI 
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compatible implanted devices. This study aimed to determine optimal predictors of the development of 
need for valve surgery; therefore, subjects who were symptomatic (n= 2 for AR, n=1 for MR) or met 
other current ACC/AHA Guideline indications for valve surgery at the time of enrollment (n=0 for AR, 
n=1 for MR [severe MR and LVESD>40 mm]) were excluded from the analysis. One subject with MR had 
ischemic rather than primary MR and was excluded. Subjects that were lost to follow-up (n=0 for AR, 
n=1 for MR) were also excluded from the final analysis resulting in a final study group of 29 
asymptomatic adults with chronic AR and 22 asymptomatic adults with chronic, primary MR. The 
etiology of AR is listed in table 1. Myxomatous disease was the etiology in all subjects with MR.  
Subjects who received care at the University of Washington had clinical information extracted 
from the medical record. For subjects without follow-up at our medical center, a standardized 
questionnaire via telephone was used to assess new cardiac symptoms, arrhythmia, cardiac 
medications, HF hospitalization, and valve surgery with date and indication. The study protocol was 
approved by the University of Washington Institution Review Board and subjects provided written 
informed consent.   
Both baseline TTE and CMR data were available to the subject’s physicians. Additional cardiac 
imaging studies were performed during the follow-up period at the discretion of the subject’s physician. 
Referral for valve surgery was undertaken according to the standard of care as recommended by the 
ACC/AHA Guideline for Management of Patients with Valvular Heart Disease.
9,10
  
The primary study endpoint was a composite of: (1) valve surgery for the primary indication of 
valve regurgitation or (2) hospitalization for HF secondary to valve regurgitation. Subjects were followed 
from enrollment date until reaching a primary study endpoint or until death, cardiac surgery for primary 
indications other than valve regurgitation or the date of their last clinical follow-up (office visit or 
telephone interview) occurring prior to April 1st, 2015. Subjects who died or underwent cardiac surgery 
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for primary indications other than valve regurgitation were censored on the date of death or cardiac 
surgery, respectively.  
 Imaging protocols have been described in detail previously.
18
 TTE and CMR were performed on 
the same day in all subjects. TTE measurements were made by two experienced observers who were 
blinded to clinical status and CMR measurements. Similarly, CMR measurements were independently 
performed by two experienced observers using a commercial analysis platform (Extended MR 
Workspace version 2.6.1, Philips Healthcare, Best, The Netherlands). Mean values from the two readers 
were used for the final analysis in the current study. For each of the imaging modalities, LV volumes 
were indexed to body surface area (BSA), as a means to adjust for differences in body size. 
For TTE, LV volumes were calculated with the two-dimensional apical biplane formula from 
apical 4-chamber and 2-chamber views with tracing of endocardial borders at end-systole and end-
diastole. For MR, regurgitant volume was calculated by the proximal isovelocity surface area (PISA) 
method with PISA flow rate of 2πr
2
 x aliasing velocity. The regurgitant orifice area was calculated as the 
PISA flow rate x maximum velocity of MR. Regurgitant volume was calculated to be regurgitant orifice 
area x velocity time integral of MR jet signal. Aortic regurgitant volume was calculated by subtracting 
forward stroke volume (FSV) across the mitral annulus (MA) from total stroke volume (TSV) through the 
LV outflow tract (LVOT) (regurgitant volume [AR]=TSVLVOT-FSVMA).  
For CMR, LV volumes were measured by tracing endocardial borders on a stack of short-axis 
images from breath-held steady-state free precession images covering the LV, from base to apex. 
Papillary muscles and trabeculations were included in the blood pool. LV end-diastolic volume (LVEDV) 
and end-systolic volume (LVESV) were calculated by summation of disks. Mitral regurgitant volume was 
calculated using the forward stroke volume (FSV) across the aortic valve obtained via the phase contrast 
method and the total LV stroke volume (TSV=LVEDV-LVESV), thus regurgitant volume (MR) =TSV-FSV.  
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AR was evaluated using aortic phase-contrast velocity mapping to calculate regurgitant volume from the 
area under the retrograde diastolic flow curve measured at the aortic sinuses.  
 Data analysis was performed with the use of ‘R’ version 3.1.1. Receiver operating characteristic 
(ROC) analysis was performed for multiple pre-defined TTE and CMR parameters obtained by baseline 
imaging according to the primary composite endpoint. The area under the curve (AUC) was calculated 
for each of the ROC curves. AUCs were compared for corresponding TTE and CMR variables (i.e. 
regurgitant volume by TTE versus CMR) by use of the methods of DeLong, et al. by using the pROC 
statistical package in ‘R’.
19
 Using the ROC analysis, an optimal threshold was derived for each imaging 
parameter that maximized sensitivity and specificity of predicting the development of the primary 
endpoint. Kaplan-Meier analysis was performed for each of the parameters by using this optimal 
threshold to form two dichotomous groups, above and below the threshold. Log-rank testing was then 
performed to compare the survival curves for each of the variables. Simple logistic regression analysis 
was also performed on each variable to determine if incremental increases in each parameter was 
associated with the primary event. A p <0.05 was considered the threshold for statistical significance.  
Results 
Baseline imaging characteristics and outcomes for all subjects with AR are shown in Table 1. Five 
of the 29 subjects with AR developed the primary endpoint, with all 5 undergoing valve surgery. 
Indications for valve surgery are listed in Table 1. Table 2 shows the baseline imaging and outcomes for 
all subjects with MR, including indications for valve surgery. Eight of the 22 subjects with MR developed 
the primary endpoint, with 7 of the 8 subjects undergoing valve surgery and 1 being hospitalized for HF 
secondary to severe MR.   
Table 3 shows the hazard ratios for each of the imaging parameters for the primary endpoint by 
simple logistic regression. For AR, indexed LV volumes by both imaging modalities were associated with 
the primary endpoint but LV diameters were not. Regurgitant volume by both modalities was also 
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associated with the primary endpoint. For MR, the only baseline imaging parameter that had an 
association with the primary endpoint was regurgitant volume by TTE.  
By ROC analysis, areas under the curve (AUC) for each of the imaging parameters are shown in 
Table 3. For AR, indexed LV volumes by TTE and regurgitant volume and fraction by CMR had the highest 
AUC, with values ≥0.90. The AUC for CMR-derived regurgitant volume and RF were significantly higher 
than the corresponding values derived by TTE by DeLong testing (Figure 1). Kaplan-Meier curves of 
LVESVi and regurgitant volume are shown in Figures 2a-d, with a significant difference between the 
survival curves for each of the imaging parameters. Of subjects with LVESVi≤40.4 mL/m
2
 or less by TTE, 
4.2% developed the primary endpoint, as compared with 80% of those with LVESVi>40.4 mL/m
2
. The 
threshold of regurgitant volume by CMR of 50 mL had 100% sensitivity for identifying subjects that 
would require valve surgery, with 50% of subjects with regurgitant volume>50 mL developing the 
primary endpoint.    
For MR, regurgitant volume by TTE was the only baseline measurement that had an AUC of ≥ 
0.80 (Table 3). There was a trend toward a higher AUC for regurgitant volume by TTE compared with 
CMR (Figure 3), but this was not statistically significant (p=0.07). Kaplan-Meier survival curves for 
regurgitant volume by TTE and CMR are shown in Figure 4. TTE-derived regurgitant volume was able to 
identify high- and low-risk subjects, with 70% of subjects with greater than 30 mL developing the 
primary endpoint compared to 8.3% of those below the threshold. There was no significant separation 
of the survival curves according to regurgitant volume by CMR.  
Discussion 
This study compared the predictive value of TTE and CMR in subjects with chronic AR or chronic, 
primary MR for development of HF or the need for valve surgery over a mean 4.4 years of follow-up. In 
subjects with AR, regurgitant volume by CMR was superior to TTE in predicting the need for valve 
surgery and had improved ability to stratify subjects into low and high-risk groups. For subjects with MR, 
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there was a trend toward superior predictive ability of regurgitant volume by TTE compared to CMR, but 
this did not reach the level of statistical significance.  
Current guidelines for management of valvular heart disease recommend TTE as the primary 
imaging method to follow subjects with AR and MR. These recommendations were based on prospective 
studies which compared TTE measurements to outcomes in subjects followed clinically or undergoing 
valve surgery.
1,4,6,7,20,21
 However, CMR has advantages compared with TTE, both for measuring LV 
parameters and for quantitating valve regurgitation, with superior reproducibility for measurement of 
LV volumes, LVEF, RF and regurgitant volume.
17,18
 While several studies have previously compared the 
diagnostic concordance of CMR and TTE for the quantification of valve regurgitation, few have studied 
which imaging modality better predicts the development of cardiac symptoms or the need for valve 
surgery in a prospective manner. 
The improved predictive ability of regurgitant volume by CMR compared to TTE in patients with 
aortic regurgitation is likely explained by improved accuracy of measurement related to the difference in 
methods for measuring these values. For TTE, quantification of regurgitant volume and fraction require 
measuring stroke volumes at the mitral annulus and the LV outflow tract, which introduces multiple 
potential sources for error and summates them in the final calculations. For CMR, regurgitant volume is 
measured directly using phase contrast flow imaging, which is less susceptible to measurement error 
and is extremely reproducible.
18
 
 Few other prospective studies have correlated CMR measurements with clinical events in 
subjects with AR. In a recent study, Myerson, et al. found that LV volumes and regurgitant volume were 
predictive of future events in 113 subjects with chronic AR, with a CMR-derived RF >33% having  85% 
sensitivity and 92% specificity for identifying subjects who progressed to valve surgery.11 Similarly, in the 
current study subjects with a CMR-derived regurgitant volume ≤50 mL/beat had a very low rate of valve 
surgery and a CMR-derived aortic RF of ≥37% had a sensitivity of 100% and specificity of 75% for the 
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need for valve surgery during an average of 4.4 years of follow-up. In addition, the current study shows 
that CMR measures of regurgitant volume predict outcomes better than regurgitant volume by TTE. 
Therefore, this study supports a role for the use of CMR in assessment of patients with AR, especially in 
cases where the severity of regurgitation is uncertain or there is apparent discrepancy between the 
degree of LV dilation and severity of regurgitation by TTE.  
In the current study, LV volume measurements (either by TTE or CMR) in subjects with AR were 
highly predictive of the need for valve surgery and performed better than LV diameter measurements. 
This finding supports the American Society of Echocardiography recommendations for measuring LV 
volumes in subjects with valve disease. TTE and CMR LV volumes had a similar predictive value for valve 
surgery with overlapping hazard ratios and similar AUCs. Our findings support the use of LV volume 
measurements, rather than LV diameter in prognosis and timing of interventions for subjects with AR. 
Further research is needed to define optimal indications for valve surgery based on LV volumes.  
In subjects with chronic MR, TTE and CMR performed similarly in their ability to predict cardiac 
symptoms or the need for valve surgery. There was a trend toward superior performance of TTE-derived 
regurgitant volume, but this did not reach the level of statistical significance. Our findings support 
previous studies showing the predictive value of quantitative measures of MR severity by TTE in 
predicting clinical outcome.
8
 Few studies have previously investigated CMR in a prospective manner to 
determine correlation between CMR assessment of MR severity and development of indications for 
valve surgery. Myerson et al. recently reported a strong correlation between severity of MR as assessed 
by CMR-derived regurgitant volume and fraction and need for mitral valve surgery; however, they also 
reported that TTE measurements did not predict the need for valve surgery.
22
 Our results are discordant 
in that we found a trend toward better prediction of outcomes with TTE as compared to CMR. The 
reason for this discordance is unclear but notable differences in study design were that 
echocardiography used in the current study was done as a part of the research protocol as opposed to 
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retrospective review of previous TTE data and that all patients (as opposed to only 49% in the Myerson 
study) underwent quantitative assessment of MR severity. Based on the results of our study, TTE 
assessment of MR severity remains an optimal approach.  
This study has several limitations. As is common in clinical practice, treating physicians used TTE 
rather than CMR for clinical follow-up of the subjects enrolled in this study. Results from subsequent TTE 
examinations may have impacted the decision to refer for valve surgery and a potential systematic bias 
in favor of baseline TTE over CMR imaging for the decision to proceed to valve surgery.  However, 
despite this concern, regurgitant volume by CMR outperformed regurgitant volume by TTE in predicting 
events in subjects with chronic AR. Furthermore, nearly all subjects with MR underwent valve surgery 
for symptomatic indications rather than imaging alone; 4 out of 7 had heart failure symptoms, 2 had 
symptomatic atrial arrhythmias and 1 had unknown indications. Another potential limitation is that the 
clinicians were not blinded to the baseline imaging. On average, LV volumes are larger for CMR 
compared to TTE, so this may influence earlier referral for valve surgery. However, this is unlikely to be 
playing a significant role given the long duration of time from baseline imaging to the primary endpoint 
with a range of 219-2099 days and mean 1073 days. Furthermore, only 1 subject that underwent valve 
surgery had a follow-up CMR, with 4.3 years between this study and valve surgery. Therefore, decisions 
were mostly based on symptomatic changes and follow-up TTE imaging, with an average of 3.7 TTEs per 
subject over the follow-up period for AR and 2.9 per subject for MR.  
A limitation of the CMR analysis technique is inclusion of papillary muscles and trabeculae in 
blood pool, which results in increased calculated LV volumes and TSV, and thus a larger derived MR 
regurgitant volume.
23–26
 Three-dimensional TTE was not used in this study, though does have some 
advantages over 2D-TTE and could be compared to CMR in future studies. Other limitations of this study 
are the modest study size and small number of primary endpoints. These limitations reduce the power 
to detect a difference between TTE and CMR (Type II error) for prediction of clinical outcomes. 
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FIGURE LEGENDS 
Figure 1. Comparison of ROC curves of regurgitant volume for subjects with aortic regurgitation 
Figure 1 Legend: ROC curves for TTE-derived (red line) and CMR-derived (blue line) regurgitant volume compared 
to clinical events in subjects with AR. Comparison of AUCs was performed using Delong testing.  The AUC is 
significantly greater for CMR-derived regurgitant volume at 0.90 as compared with an AUC of 0.67 for TTE-derived 
regurgitant volume (p<0.05). This demonstrates that quantification of aortic regurgitation severity by CMR had 
better association with clinical outcomes than quantification by TTE. AUC, area under the curve; CMR, cardiac 
magnetic resonance; ROC, receiver operating characteristic; TTE, transthoracic echocardiography.   
 
Figure 2. Kaplan Meier event-free survival for subjects with aortic regurgitation according to LVESVi and 
regurgitant volume (RVol) 
Figure 2 Legend: Kaplan-Meier curves showing survival free from the primary endpoint for subjects with AR using 
LVESVi measured by TTE (a) and CMR (b) and using regurgitant volume (RVol) by TTE (c) and CMR (d). Subjects 
were dichotomized into high- and low-risk groups according to optimal sensitivity of the test. Comparison of curves 
was performed by log-rank testing, with p-value shown in figures. These figures show that LVESVi and regurgitant 
volume measured by both imaging modalities were able to define low- and high-risk groups with a significant 
difference in endpoint-free survival between these groups. CMR, cardiac magnetic resonance; LVESVi, LV end-
systolic volume-indexed; RVol, regurgitant volume; TTE, transthoracic echocardiography.   
 
Figure 3. Comparison of ROC curves of regurgitant volume for subjects with mitral regurgitation 
Figure 3 Legend: ROC curves for TTE-derived (red line) and CMR-derived (blue line) regurgitant volume compared 
to clinical events in subjects with MR. Comparison of AUCs was performed using Delong testing.  The AUC for TTE-
derived regurgitant volume at 0.84 was greater than an AUC of 0.64 for CMR-derived regurgitant volume; 
however, this relationship did not reach statistical significance (p=0.07). This demonstrates that there was a non-
significant trend toward better correlation between TTE-derived regurgitant volume than CMR-derived regurgitant 
volume in mitral regurgitation. AUC, area under the curve; CMR, cardiac magnetic resonance; ROC, receiver 
operating characteristic; TTE, transthoracic echocardiography.  
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Figure 4. Kaplan Meier event-free survival for subjects with mitral regurgitation according to regurgitant volume 
(RVol) 
Figure 4 Legend: Kaplan-Meier curves showing survival free from the primary endpoint for subjects with MR for 
regurgitant volume (RVol) by TTE (a) and CMR (b). Comparison of survival curves was performed by log-rank 
testing, with p-value shown in figures. Figure 4a shows significant separation of the survival curves for TTE-derived 
regurgitant volume (p<0.005), demonstrating a significant difference between low- and high-risk groups. Figure 4b 
shows that there is no significant separation of the survival curves for CMR-derived regurgitant volume with 
p=0.12 for difference between the curves. These results suggest that TTE-derived regurgitant volume had better 
correlation with the primary endpoint than CMR-derived regurgitant volume in MR. CMR, cardiac magnetic 
resonance; RVol, regurgitant volume; TTE, transthoracic echocardiography.   
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Table 1. Clinical, imaging characteristics at study baseline and outcomes shown for each subject with 
aortic regurgitation.   
  
 
Age represents age at baseline imaging. Imaging parameters listed were obtained at time of baseline 
imaging. Duration of follow-up represents time from baseline imaging to either development of the 
Subject 
# 
Etiology 
of Valve 
disease 
Age 
(years) 
TTE 
RVol 
(mL) 
CMR 
RVol 
(mL) 
TTE 
LVESVi 
(mL/m
2
) 
CMR 
LVESVi 
(mL/m
2
) 
Duration 
follow-up 
(days) 
Primary 
Endpoint 
1 BAV 24 0.0 7.8 11.9 30.7 2129 No 
2 
Aortic 
aneurysm 25 18.4 70.0 29.0 55.3 2242 Yes (HF) 
3 
Aortic 
aneurysm 26 84.8 97.3 35.8 72.4 1806 No 
4 
Aortic 
aneurysm 31 65.2 25.8 21.9 39.2 785 No 
5 Prior IE 33 8.3 43.3 28.8 46.2 1806 No 
6 BAV 34 29.6 30.5 24.0 26.2 1984 No 
7 BAV 37 0.0 42.4 26.6 50.8 2065 No 
8 
Abnormal 
leaflet 37 144.1 24.6 26.4 46.8 1309 No 
9 BAV 37 158.1 114.8 40.3 76.3 554 No 
10 BAV 38 32.8 24.3 22.5 41.2 1989 No 
11 BAV 41 0.0 22.1 32.9 55.7 2387 No 
12 BAV 41 89.2 123.6 49.4 79.9 2099 Yes (LVESD) 
13 BAV 42 0.0 6.4 18.2 24.0 1648 No 
14 BAV 42 31.3 35.8 22.5 40.3 2163 No 
15 BAV 42 49.5 9.9 17.3 35.4 2281 No 
16 BAV 45 35.1 40.8 40.4 73.7 2183 No 
17 
Aortic 
aneurysm 45 38.9 19.9 11.1 31.2 1921 No 
18 
Aortic 
aneurysm 49 59.0 48.5 31.7 49.5 2065 No 
19 BAV 51 96.4 73.5 38.2 61.2 2001 No 
20 BAV 58 36.0 29.5 42.9 64.1 2049 No 
21 Prior IE 60 72.5 122.2 40.5 74.4 675 Yes (LVEDD) 
22 BAV 61 31.0 32.0 28.7 50.3 1718 No 
23 
Aortic 
aneurysm 61 50.9 31.9 31.0 49.4 1885 No 
24 BAV 62 73.2 75.2 39.0 75.1 1848 No 
25 BAV 65 83.7 52.7 43.2 66.9 1766 Yes (LVEF) 
26 BAV 65 87.3 28.1 21.3 34.4 1582 No 
27 BAV 68 106.5 14.7 31.8 57.1 1781 No 
28 
Leaflet 
prolapse 68 108.1 83.5 52.2 67.6 504 Yes (LVEF) 
29 BAV 77 86.3 73.8 24.7 63.0 2059 No 
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primary endpoint, last clinical follow-up, or censoring for other reasons. The indications for valve surgery 
are listed in parentheses for those patients experiencing the primary endpoint, with HF indicating 
development of heart failure; LVESD>50 mm, LVEDD>65 mm and LVEF <50% were also indications for 
valve surgery and are listed. BAV, bicuspid aortic valve; CMR, cardiac magnetic resonance; LVEDD, LV 
end-diastolic diameter; LVEF, LV ejection fraction; LVESD, LV end-systolic diameter; LVESVi, LV end-
systolic volume-indexed; Prior IE; prior infective endocarditis; RVol, regurgitant volume; TTE, 
transthoracic echocardiography.  
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Table 2. Clinical, imaging characteristics at study baseline and outcomes shown for each subject with 
mitral regurgitation.    
Subject 
# 
Age 
(years) 
TTE 
RVol 
(mL) 
CMR 
RVol 
(mL) 
TTE 
LVESVi 
(mL/m2) 
CMR 
LVESVi 
(mL/m2) 
Duration 
follow-up (days) 
Primary 
endpoint 
1 29 31.7 32.5 30.4 52.7 565 Yes (HF) 
2 30 60.1 54.2 36.7 52.6 1442 No 
3 32 15.5 67.6 13.2 50.9 1848 No 
4 38 23.8 33.7 26.9 37.6 1555 No 
5 44 16.2 9.7 19.3 31.9 1441 Yes (unknown) 
6 45 3.0 11.1 16.1 28.2 1869 No 
7 45 32.6 48.2 22.5 46.3 1393 No 
8 49 53.5 45.1 36.5 46.1 625 Yes (HF) 
9 50 95.9 48.7 26.2 49.5 1799 No 
10 51 19.5 26.2 25.6 41.2 1428 No 
11 52 7.95 32.4 29.0 45.1 2185 No 
12 53 5.1 16.5 10.1 25.2 2317 No 
13 55 41.7 62.3 21.3 49.8 925 Yes (HF) 
14 58 95.0 97.3 23.3 49.9 1989 Yes (HF hosp.) 
15 59 41.8 19.3 16.4 37.7 1175 Yes (AF, LVESD) 
16 60 9.4 22.8 37.7 62.0 1435 No 
17 63 76.0 37.1 30.9 47.1 1025 Yes (HF) 
18 64 12.5 20.6 23.4 36.0 1428 No 
19 66 25.7 35.1 22.7 44.1 904 No 
20 66 104.9 60.9 28.9 57.3 219 Yes (AF, LVESD) 
21 68 9.8 8.7 6.4 30.5 1842 No 
22 77 23.2 21.8 25.6 46.1 1805 No 
 
All patients had myxomatous disease as the etiology for mitral regurgitation. Age represents age at 
baseline imaging. Imaging parameters listed were obtained at time of baseline imaging. Duration of 
follow-up represents time from baseline imaging to either development of the primary endpoint, last 
clinical follow-up, or censoring for other reasons. The indications for valve surgery are listed in 
parentheses for those patients experiencing the primary endpoint, with HF indicating development of 
heart failure symptoms; LVESD≥40 mm and symptomatic atrial fibrillation (AF) were also indications and 
listed in table. One subject underwent valve surgery for unknown indications. One subject met the 
endpoint for hospitalization for heart failure (HF hosp.). CMR, cardiac magnetic resonance; LVESD, LV 
end-systolic diameter; LVESVi, LV end-systolic volume-indexed; RVol, regurgitant volume; TTE, 
transthoracic echocardiography.  
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Table 3. Correlation of baseline imaging with primary endpoint by simple logistic regression and ROC 
analysis for aortic and mitral regurgitation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hazard ratios from simple logistic regression are shown for correlation between baseline imaging 
parameter and primary endpoint, by incremental unit shown in table; 95% confidence intervals shown in 
parentheses. Area under the curve (AUC) by ROC analysis shown for both TTE and CMR. DeLong p-value 
is the comparison of the AUC for each imaging parameter for TTE vs. CMR. *Indicates significant to 
p<0.05. AUC, area under the curve; CMR, cardiac magnetic resonance; LVEDDi, LV end-diastolic 
diameter-indexed; LVEDVi, LV end-diastolic volume-indexed; LVEF, LV ejection fraction; LVESDi, LV end-
systolic diameter-indexed; LVESVi, LV end-systolic volume-indexed; TTE, transthoracic 
echocardiography.   
Imaging 
Parameter 
Hazard Ratio 
TTE 
Hazard Ratio 
CMR 
AUC 
TTE 
AUC 
CMR 
DeLong 
p-value 
Aortic regurgitation (n=29) 
LVEDVi 
1.93 (1.17-3.18) 
per 10 mL/m
2
 
1.37 (1.05-1.78) 
per 10 mL 0.91 0.82 0.11 
LVESVi 
8.25 (1.58-43.17) 
per 10 mL/m
2
 
3.03 (1.02-9.03) 
per 10 mL/m
2
 0.91 0.84 0.28 
LVEF 
0.89 (0.74-1.06) 
per 1% 
0.91 (0.73-1.14) 
per 1% 0.63 0.68 0.8 
Regurgitant 
Volume 
1.31 (1.01-1.70) 
per 10 mL 
1.46 (1.10-1.94) 
per 10 mL 0.67 0.90 0.044* 
Regurgitant 
Fraction 
1.08 (0.99-1.16) 
per 1% 
1.10 (1.02-1.19) 
per 1% 0.59 0.90 0.038* 
LVEDDi 
1.17 (0.93-1.46) 
per 1 mm/m2 - 0.64 - - 
LVESDi 
1.12 (0.85-1.49) 
per 1 mm/m2 - 0.62 - - 
Mitral regurgitation (n=22) 
LVEDVi 
1.71 (0.90-3.26) 
per 10 mL/m
2 
1.44 (0.96-2.15) 
per 10 mL/m
2
 0.72 0.70 0.72 
LVESVi 
1.73 (0.69-4.35) 
per 10 mL/m
2 
1.71 (0.77-3.82) 
per 10 mL/m
2
 0.58 0.67 0.44 
LVEF 
0.99 (0.92-1.07) 
per 1% 
0.99 (0.89-1.12) 
per 1%
 
0.50 0.56 0.74 
Regurgitant 
Volume 
1.22 (1.01-1.48) 
per 10 mL 
1.13 (0.88-1.45) 
per 10 mL
 
0.84 0.64 0.07 
Regurgitant 
Fraction - 
1.02 (0.98-1.07) 
per 1% - 0.62 - 
LVEDDi 
1.18 (0.97-1.44) 
per 1 mm/m
2
 - 0.69 - - 
LVESDi 
1.16 (0.85-1.60) 
per 1 mm/m
2 
- 0.57 - - 
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